Orphan Therapeutics Accelerator Inc
Nonprofit profile at a glance
- EIN
- 993630868
- IRS 990-EZ coverage
- 2024–2024
- Forms available
- Form 990-EZ 2024
- Location
- Andover, MA, USA
- Phone
- 2159158364
- Rating confidence
- Limited
- Sector
- Specifically Named Diseases Research
Reported finances
- Revenue
- $0
- Expenses
- $364,147
- Assets
- $0
- Liabilities
- $364,147
Source: IRS Form 990-EZ. Selected filing: tax year 2024. Amounts in USD.
Leadership & pay
6 people listed
Executive titles in this filing
- Donald Craig Martin (Chief Executive Officer / Board Director)
- Elizabeth White (Secretary-Executive Vice President)
- Deanna Portero (Vice President, Partnerships and Innovation)
- Nandan Padukone (Treasurer-Executive Vice President)
People named in this filing
- Donald Craig Martin (Chief Executive Officer / Board Director)
- Elizabeth White (Secretary-Executive Vice President)
- Deanna Portero (Vice President, Partnerships and Innovation)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990-EZ. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
The specific and primary purpose of the Orphan Therapeutics Accelerator is to engage in charitable and scientific activities within the meaning of Section 501(c)(3) of the Code, including, but not limited to, the following activities: a. Providing, expanding access to, and resolving barriers to the development of therapeutic resources in the form of drugs, therapies, and other related treatments to rare diseases (collectively, the "Therapies"), so as to provide accessible treatments and potential cures to rare diseases that, otherwise, would not be available (such purposes, the "Charitable Purposes"). b. Addressing and resolving scientific barriers to development of the Therapies, which the Accelerator will accomplish via research as it acquires and shepherds the Therapies through late-stage clinical trials, so as to provide accessible treatments and potential cures for rare diseases without known and accessible treatments (such purposes, the "Scientific Purposes").
What it reported doing in 2024
In 2024, the Orphan Therapeutics Accelerator was formed. In this initial year of operating, the organization developed a new model to bring rare disease programs that had been halted by for-profit companies through development so that these medicines could be made accessible to rare disease patients in need. We evaluated potential medicines, developed partnerships to support our model, and connected with potential funding sources.
Operating model
- Revenue model
- No positive adjusted resources. The filing reports no positive adjusted operating resources.
- Distribution model
- Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.
The verdict
- The available evidence is not sufficient to produce an overall rating for this filing. This is not a warning sign.
Rating breakdown
- Financial Efficiency: 78
- Transparency & Controls: 82
- Sustainability: 1
- Growth: NotEnoughData
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: Limited
- Program expense ratio: 77.6%; rating input score 78
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 52nd percentile among comparable filings
- Major donor itemization: Limited
Sustainability
- Operating margin: Limited
- Total-asset coverage ratio: 0; rating input score 2; 2nd percentile among comparable filings
- Liabilities to assets ratio: Limited
- Officer compensation ratio: 82.9%; rating input score 0; 0th percentile among comparable filings
Growth
- Program expense growth: Limited
- Revenue growth: Limited
- Asset growth: Limited
Details
- Where the money goes: 77.6% of spending went to programs
- Governance: Filed governance answers
- Accomplishments: 1 filed program accomplishment · $283K in reported program spending
- Leadership: top reported pay $0 · 6 people listed
- Consistency: 9 of 9 current checks pass
- Schedules: 2 filed schedules
- Contacts: How to reach this organization
- Money network: 3 filed money-flow records
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Sustainability: Total-asset coverage ratio scored 2/100.
- High — Sustainability: Officer compensation ratio scored 0/100.